Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial
Question
Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial
Direct answer
Genmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways. — bullish pressure on GMAB.
- Original publisher
- Market Ontology
- Evidence through
- 2026-10-04
- Published
- 2026-10-20
- Revision
- 1 · 2026-10-20
Cite as: Market Ontology, “Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial”, revision 1, evidence through 2026-10-04. https://marketontology.com/catalysts/2026-10-04/genmab-reports-45-9-response-rate-in-phase-2-ovarian-cancer-antibody-drug-trial-2247ad
| Asset | Direction | Timeframe | Channel | Score |
|---|---|---|---|---|
| GMAB | ▲Bull | 1–5 days | Catalyst Driven | 59 |
Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug Trial
Genmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways. — bullish pressure on GMAB.
Genmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways.
- SummaryGenmab presented results for its antibody-drug conjugate candidate rinatabart sesutecan in advanced ovarian cancer patients resistant to platinum chemotherapy. With a 12.1-month median response duration and 9.5-month progression-free survival, the data supports advancing the program toward registrational development pathways.
- GMABDirect directional exposure
Illustrative, not advice
- Crowded positioning may already reflect the move
- Counter-catalyst could neutralize the thesis before window closes
- GMAB closes below pre-catalyst level on rising volume
- Catalyst narrative is officially walked back or contradicted
- Cross-asset confirmation (rates / FX / vol) reverses direction
- GMAB price vs. pre-event level
- GMAB volume vs. 20-day average
What happened next
Price follow-up pending — no stored daily closes for these assets yet.
Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.
No verifiable public source recorded for this card.
Related catalysts
- 2026-10-04Genmab Reports 45.9% Response Rate in Phase 2 Ovarian Cancer Antibody-Drug TrialGMAB XBI
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 RAINFOL-01 Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Rina-S ADC Delivers 45.9% Response Rate in Platinum-Resistant Ovarian CancerGMAB
- 2026-10-04Genmab Reports 45.9% ORR in Phase 2 Platinum-Resistant Ovarian Cancer TrialGMAB
- 2026-10-04Genmab Phase 2 Trial for Rina-S Demonstrates 45.9% ORR in Ovarian CancerGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
- 2026-10-04Genmab Phase 2 Ovarian Cancer Trial Demonstrates 45.9% ORR and 9.5M Median PFSGMAB
See today's live cards
Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.